迈威生物注射用7MW4911临床试验申请获受理

Core Viewpoint - The company has received formal acceptance of its clinical trial application for the injectable 7MW4911 from the National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the FDA, indicating progress in its drug development pipeline [1] Group 1 - The injectable 7MW4911 is an innovative antibody-drug conjugate (ADC) targeting cadherin 17 (CDH17) developed based on the company's proprietary IDDC antibody conjugation technology platform [1] - The acceptance of the clinical trial application by NMPA marks a significant milestone for the company in advancing its drug candidate [1] - The receipt of the IND Acknowledgement Letter from the FDA confirms that the company has submitted its IND application for 7MW4911, facilitating its entry into the U.S. market [1]